Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

@article{Gordon2001PhaseIS,
  title={Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.},
  author={Michael S Gordon and Kim A Margolin and Moshe Talpaz and George W. Sledge and Eric Holmgren and Robert M. Benjamin and Susan Stalter and Steven Shak and Donna Adelman},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 3},
  pages={843-50}
}
PURPOSE We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with cancer. PATIENTS AND METHODS Cohorts of patients with metastatic cancer having failed prior therapy entered a phase I trial of rhuMAb VEGF administered by a 90-minute intravenous infusion at doses from 0.1 to 10.0 mg/kg on days 0, 28, 35, and 42. Patients underwent pharmacokinetic sampling on day 0 and had serum samples… CONTINUE READING
Highly Influential
This paper has highly influenced 16 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 326 extracted citations

Similar Papers

Loading similar papers…